LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Stock List・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Closed

SectorHealthcare

0.17

Buy Sell

Overview

Share price change

24h

Current

Min

0.17

Max

0.17

Key metrics
By Trading Economics
Income	-2.5M -37M
Sales	14M 14M
EPS	-0.111
Profit margin	-262.996
Employees	142
EBITDA	10M -23M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+5900% upside

Dividends
By Dow Jones
Next Earnings	11 May 2026

Market Stats
By TradingEconomics
Market Cap	-51M 74M
Previous open	0.17
Previous close	0.17

News Sentiment

By Acuity

100%

338 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5207 / 0.7223 Support & Resistance

Sangamo Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 May 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 May 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 May 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 May 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 May 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 May 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 May 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 May 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 May 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 May 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 May 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 May 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 May 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 May 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 May 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8 May 2026, 15:20 UTC

Market Talk

Earnings

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 May 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 May 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 May 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Peer Comparison

Price change

Sangamo Therapeutics Inc Forecast

Price Target

By TipRanks

5900% upside

12 Months Forecast

Average 6 USD 5900%

High 10 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forSangamo Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Sangamo Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.5207 / 0.7223Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

338 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.